Latest CKD Stories

Acquisition Includes Replidea(TM) and Alpharen(TM), Both in Phase 3 Clinical Trials with Kidney Disease Patients MARKHAM, ON, Jan. 8, 2013 /PRNewswire/ - Cytochroma today announced that it has entered into a definitive agreement with OPKO Health, Inc. (NYSE:OPK) under which Cytochroma, a privately held pharmaceutical company with operations in Markham, ON and Bannockburn, IL, will be acquired by OPKO. Through this transaction, OPKO will acquire worldwide rights to Cytochroma's two...

MARKHAM, ON, Sept. 20, 2012 /PRNewswire/ - Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules ("CTAP101 Capsules") in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The newly initiated trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of CTAP101 Capsules as a new treatment for SHPT...

MARKHAM, ON, May 11, 2012 /PRNewswire/ - Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules.  In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.  These findings, as well as two other presentations on CTAP101 Capsules, are being featured at the National Kidney...

MARKHAM, ON, April 3, 2012 /PRNewswire/ - Cytochroma today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for US Patent Application # 13/244,945.  This patent application, entitled "Method for Treating Secondary Hyperparathyroidism in CKD", covers the anticipated method of use of the Company's lead product, CTAP101 Capsules, which is in phase 3 development for treating patients with Stage 3 or 4 chronic kidney disease (CKD),...

MARKHAM, ON, July 26, 2011 /PRNewswire/ - Cytochroma today announced that it has closed an equity investment of $1 million from the Investment Accelerator Fund, a fund of the Province of Ontario that invests in emerging Ontario technology companies.  The investment is designed to advance and accelerate the Company's development of CTAP101 Capsules, a product currently in a Phase 2b study for the treatment of secondary hyperparathyroidism associated with vitamin D insufficiency...

MARKHAM, ON, Feb. 17 /PRNewswire/ - Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD). "Vitamin D insufficiency in CKD patients is a significant problem associated with increased mortality and morbidity and for which no approved treatment is available," stated Joel Z. Melnick, M.D., Cytochroma's Vice...

By Raymond, Colette B Wazny, Lori D; Honcharik, Patricia L Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin reuptake inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine. Although very little research has been conducted on the use of antidepressants in CKD, health care providers should be aware of renal dose adjustments for these agents, drug...